Proteins binding NKG2D, CD16 and CLEC12A

Patent metadata

Field	Value
Publication number	US-12157771-B2
Application number	US-202117308691-A
Country	US
Kind code	B2
Filing date	May 5, 2021
Priority date	May 6, 2020
Publication date	Dec 3, 2024
Grant date	Dec 3, 2024

Abstract

Described herein are multispecific binding proteins that bind NKG2D receptor, CD16, and CLEC12A, pharmaceutical compositions comprising the multispecific binding proteins, and therapeutic methods useful for the treatment of cancer.

First claim

What is claimed is:

1. A protein comprising:
(a) a first antigen-binding site that binds NKG2D;
(b) a second antigen-binding site that binds CLEC12A; and
(c) an antibody Fc domain or a portion thereof sufficient to bind CD16, or a third antigen-binding site that binds CD16,
wherein the first antigen-binding site comprises a heavy chain variable domain (VH) comprising a VH-complementarity-determining region 1 (VH-CDR1) comprising the amino acid sequence of SEQ ID NO:81, a VH-complementarity-determining region 2 (VH-CDR2) comprising the amino acid sequence of SEQ ID NO:82, and a VH-complementarity-determining region 2 (VH-CDR3) comprising the amino acid sequence of SEQ ID NO:112, wherein amino acid X within SEQ ID NO: 112 is M, L, I, V, Q, or F; and a light chain variable domain (VL) comprising a VL-CDR1 comprising the amino acid sequence of SEQ ID NO:86, a VL-CDR2 comprising the amino acid sequence of SEQ ID NO:77, and a VL-CDR3 comprising the amino acid sequence of SEQ ID NO: 87; and
wherein the second antigen-binding site comprises a VH comprising a VH-CDR1 comprising the amino acid sequence of SEQ ID NO:137, a VH-CDR2 comprising the amino acid sequence of SEQ ID NO:272, and a VH-CDR3 comprising the amino acid sequence of SEQ ID NO: 273; and a VL comprising a VL-CDR1 comprising the amino acid sequence of SEQ ID NO:140, a VL-CDR2 comprising the amino acid sequence of SEQ ID NO: 141, and a VL-CDR3 comprising the amino acid sequence of SEQ ID NO: 142.

2. The protein of claim 1 , wherein the VH of the first antigen-binding site comprises an amino acid sequence at least 90% identical to SEQ ID NO:95, and the VL of the first antigen-binding site comprises an amino acid sequence at least 90% identical to SEQ ID NO:85.

3. The protein of claim 2 , wherein the VH of the first antigen-binding site comprises the amino acid sequences of SEQ ID NO:95, and the VL of the first antigen-binding site comprises the amino acid sequences of SEQ ID NO:85.

4. A protein comprising:
(a) a first antigen-binding site that binds NKG2D;
(b) a second antigen-binding site that binds CLEC12A; and
(c) an antibody Fc domain or a portion thereof sufficient to bind CD16, or a third antigen-binding site that binds CD16,

wherein the first antigen-binding site comprises:
(i) a VH comprising a VH-CDR1 comprising the amino acid sequence of SEQ ID NO:81, a VH-CDR2 comprising the amino acid sequence of SEQ ID NO:82, and a VH-CDR3 comprising the amino acid sequence of SEQ ID NO:97; and a VL comprising a VL-CDR1 comprising the amino acid sequence of SEQ ID NO:86, a VL-CDR2 comprising the amino acid sequence of SEQ ID NO:77, and a VL-CDR3 comprising the amino acid sequence of SEQ ID NO:87; or
(ii) a VH comprising a VH-CDR1 comprising the amino acid sequence of SEQ ID NO:297, a VH-CDR2 comprising the amino acid sequence of SEQ ID NO:298, and a VH-CDR3 comprising the amino acid sequence of SEQ ID NO:97; and a VL comprising a VL-CDR1 comprising the amino acid sequence of SEQ ID NO:86, a VL-CDR2 comprising the amino acid sequence of SEQ ID NO:77, and a VL-CDR3 comprising the amino acid sequence of SEQ ID NO:87; and
wherein the second antigen-binding site comprises a VH comprising a VH-CDR1 comprising the amino acid sequence of SEQ ID NO:137, a VH-CDR2 comprising the amino acid sequence of SEQ ID NO:272, and a VH-CDR3 comprising the amino acid sequence of SEQ ID NO: 273; and a VL comprising a VL-CDR1 comprising the amino acid sequence of SEQ ID NO:140, a VL-CDR2 comprising the amino acid sequence of SEQ ID NO:141, and a VL-CDR3 comprising the amino acid sequence of SEQ ID NO: 142.

5. The protein of claim 4 , wherein the VH of the first antigen-binding site comprises the VH-CDR1 comprising the amino acid sequence of SEQ ID NO:81, the VH-CDR2 comprising the amino acid sequence of SEQ ID NO:82, and the VH-CDR3 comprising the amino acid sequence of SEQ ID NO:97; and the VL of the first antigen-binding site comprises the VL-CDR1 comprising the amino acid sequence of SEQ ID NO:86, the VL-CDR2 comprising the amino acid sequence of SEQ ID NO:77, and the VL-CDR3 comprising the amino acid sequence of SEQ ID NO:87.

6. The protein of claim 4 , wherein the VH of the first antigen-binding site comprises the VH-CDR1 comprising the amino acid sequence of SEQ ID NO:297, the VH-CDR2 comprising the amino acid sequence of SEQ ID NO:298, and the VH-CDR3 comprising the amino acid sequence of SEQ ID NO:97; and the VL of the first antigen-binding site comprises the VL-CDR1 comprising the amino acid sequence of SEQ ID NO:86, the VL-CDR2 comprising the amino acid sequence of SEQ ID NO:77, and the VL-CDR3 comprising the amino acid sequence of SEQ ID NO:87.

7. The protein of claim 6 , wherein the VH of the first antigen-binding site comprises an amino acid sequence at least 90% identical to SEQ ID NO:95, and the VL of the first antigen-binding site comprises an amino acid sequence at least 90% identical to SEQ ID NO:85.

8. The protein of claim 7 , wherein the VH of the first antigen-binding site comprises the amino acid sequences of SEQ ID NO:95, and the VL of the first antigen-binding site comprises the amino acid sequences of SEQ ID NO:85.

9. The protein of claim 5 , wherein the VH of the first antigen-binding site comprises an amino acid sequence at least 90% identical to SEQ ID NO:95, and the VL of the first antigen-binding site comprises an amino acid sequence at least 90% identical to SEQ ID NO:85.

10. The protein of claim 9 , wherein the VH of the first antigen-binding site comprises the amino acid sequences of SEQ ID NO:95, and the VL of the first antigen-binding site comprises the amino acid sequences of SEQ ID NO:85.

11. A protein comprising:
(a) a first antigen-binding site comprising a Fab fragment that binds NKG2D, wherein the Fab fragment that binds NKG2D comprises a VH comprising a VH-CDR1 comprising the amino acid sequence of SEQ ID NO:81, a VH-CDR2 comprising the amino acid sequence of SEQ ID NO:82, and a VH-CDR3 comprising the amino acid sequence of SEQ ID NO:97; and a VL comprising a VL-CDR1 comprising the amino acid sequence of SEQ ID NO:86, a VL-CDR2 comprising the amino acid sequence of SEQ ID NO:77, and a VL-CDR3 comprising the amino acid sequence of SEQ ID NO:87;
(b) a second antigen-binding site comprising a scFv that binds CLEC12A, wherein the scFv that binds CLEC12A comprises a VH comprising a VH-CDR1 comprising the amino acid sequence of SEQ ID NO:137, a VH-CDR2 comprising the amino acid sequence of SEQ ID NO:272, and a VH-CDR3 comprising the amino acid sequence of SEQ ID NO:273; and a VL comprising a VL-CDR1 comprising the amino acid sequence of SEQ ID NO:140, a VL-CDR2 comprising the amino acid sequence of SEQ ID NO:141, and a VL-CDR3 comprising the amino acid sequence of SEQ ID NO:142; and
(c) an antibody Fc domain or a portion thereof sufficient to bind CD16.

12. The protein of claim 11 , wherein
(i) the VH of the Fab fragment that binds NKG2D comprises an amino acid sequence at least 90% identical to SEQ ID NO:95, and the VL of the Fab fragment that binds NKG2D comprises an amino acid sequence at least 90% identical to SEQ ID NO:85; and
(ii) the VH of the scFv that binds CLEC12A comprises an amino acid sequence at least 90% identical to SEQ ID NO:335, and the VL of the scFv that binds CLEC12A comprises an amino acid sequence at least 90% identical to SEQ ID NO:336.

13. The protein of claim 11 , wherein the scFv that binds CLEC12A comprises an amino acid sequence of SEQ ID NO:274.

14. The protein of claim 11 , wherein the antibody Fc domain or the portion thereof comprises an amino acid sequence at least 90% identical to SEQ ID NO:118, and a first polypeptide chain of th

Assignees

• Dragonfly Therapeutics Inc

Inventors

• Baruah Hemanta
• Chang Gregory P
• Cheung Ann F
• Fallon Daniel
• Grinberg Asya
• Juo Zong Sean
• Morgan Christopher Ryan

Classifications

• C07K2317/622

  Single chain antibody (scFv) · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/53

  Hinge · CPC title

• C07K2317/515

  Complete light chain, i.e. VL + CL · CPC title

• C07K16/283

  against Fc-receptors, e.g. CD16, CD32, CD64 (CD23 C07K16/2851) · CPC title